HOPKINTON, Mass., Aug. 8, 2011 /PRNewswire/ — Caliper Life
Sciences, Inc. (NASDAQ:
CALP) today announced that it has favorably settled two
lawsuits with Carestream Health, Inc.
In the first lawsuit, filed in February 2010, Caliper, its
wholly owned subsidiary, Xenogen, and Stanford University alleged
that Carestream’s marketing and sales of its instrument systems
induced infringement of seven imaging patents that are exclusively
licensed to Xenogen by Stanford University.
In the second lawsuit, filed in July 2010, Carestream alleged
that Caliper’s Lumina XR system infringed a Carestream imaging
patent (U.S. Patent No. 7,734,325).
To settle these lawsuits, Carestream and Caliper have agreed (i)
to dismiss their respective claims and counterclaims; (ii) that
Carestream will not market and sell in-vivo optical imaging systems
for certain applications covered by patents licensed from Stanford
by Xenogen and Caliper; and (iii) that Carestream will not assert
that the Lumina XR system as currently configured and sold by
Caliper infringes any of Carestream’s patents.
Caliper was represented by Mark Fox Evens and Eldora Ellison,
Ph.D. of the law firm Sterne, Kessler, Goldstein & Fox,
P.L.L.C. The two suits are (i) Caliper Life Sciences, et
al. v. Carestream Health., Civil Action No.: 4:10-cv-02079-PJH
(N.D.Ca.) & (ii) Carestream Health, Inc. v. Caliper Life
Sciences, Case No.: 10-cv-00381(WMC)(SLC) (W.D.Wis.).
About Caliper Life Sciences
Caliper Life Sciences is a premier provider of cutting-edge
technologies enabling researchers in the life sciences industry to
create life-saving and enhancing medicines and diagnostic tests
more quickly and efficiently. Caliper is aggressively
innovating new technology to bridge the gap between in vitro assays
and in vivo results and then translating those results in
‘/>”/>
